Ufl1 and Ufbp1 play critical roles in preventing liver fibrosis, steatohepatitis, and HCC by acting as inhibitors of the mTOR pathway, highlighting their potential as therapeutic targets for liver diseases (89). This evidence concerns the gene UFL1 and Hepatic fibrosis.